Acyclovir Renal Dose Adjustment
In patients with reduced renal function, acyclovir dosing must be adjusted based on creatinine clearance to prevent nephrotoxicity and neurotoxicity, with dose reductions ranging from every-12-hour dosing for moderate impairment to every-24-hour dosing for severe impairment. 1, 2
Intravenous Acyclovir Dose Adjustments
The following table provides specific dose modifications based on creatinine clearance for IV acyclovir:
| Creatinine Clearance | Recommended IV Dose |
|---|---|
| > 50 mL/min | No adjustment: 5–10 mg/kg every 8 hours |
| 25–50 mL/min | 5–10 mg/kg every 12 hours |
| 10–24 mL/min | 5–10 mg/kg every 24 hours |
| < 10 mL/min | 2.5–5 mg/kg every 24 hours |
| Hemodialysis | 2.5–5 mg/kg every 24 hours; administer dose after dialysis session |
Key Rationale for Dose Reduction
- Acyclovir is 62–91% renally excreted, making dose adjustment mandatory in renal impairment to prevent drug accumulation. 1, 4
- The terminal half-life increases dramatically from 2.5–3 hours in normal renal function to approximately 19.5 hours in anuric patients. 5
- Hemodialysis removes approximately 60% of acyclovir over a 6-hour session, with a dialysis clearance of 81.8 mL/min, necessitating post-dialysis supplementation. 5
Oral Acyclovir Dose Adjustments
For oral formulations, the FDA label provides the following modifications:
| Creatinine Clearance | Recommended Oral Dose |
|---|---|
| > 10 mL/min | No adjustment for 200 mg every 4 hours or 400 mg every 12 hours |
| 0–10 mL/min | 200 mg every 12 hours (for all indications) |
| Hemodialysis | 200 mg every 12 hours; give additional dose after each dialysis |
Specific Oral Regimen Adjustments by Indication
- Herpes zoster (800 mg every 4 hours):
- CrCl > 25 mL/min: 800 mg every 4 hours, 5× daily
- CrCl 10–25 mL/min: 800 mg every 8 hours
- CrCl 0–10 mL/min: 800 mg every 12 hours 2
Critical Monitoring and Nephrotoxicity Prevention
Nephrotoxicity occurs in up to 20% of patients after approximately 4 days of IV acyclovir therapy, manifesting as crystalluria, rising serum creatinine, or obstructive nephropathy. 1, 6
Prevention Strategies
- Maintain aggressive IV hydration throughout treatment to prevent intratubular crystal precipitation. 1, 3
- Monitor renal function (serum creatinine, urine output) at baseline, daily during the first week, then every 2–3 days. 1, 3
- Infuse acyclovir slowly over 1 hour rather than as a rapid bolus to reduce crystal formation. 3
- Avoid doses exceeding 500 mg/m²/dose or 15 mg/kg/dose in children outside the neonatal period, as higher doses significantly increase nephrotoxicity risk (OR 3.81 for doses >15 mg/kg). 6
Neurotoxicity Risk in Renal Failure
Neurotoxicity is an increasingly recognized complication in dialysis-dependent patients, even with dose-adjusted regimens, presenting 2–4 days after treatment initiation. 7, 8, 9
Clinical Manifestations
- Mental confusion, psychomotor agitation, hallucinations
- Dysarthria, ataxia, involuntary movements, paresis
- Dizziness, blurred vision, dysgeusia, anosmia 7, 9
Recommended Dosing for End-Stage Renal Disease
- Loading dose: 400 mg orally
- Maintenance dose: 200 mg orally twice daily
- Post-hemodialysis supplementation: Additional 400 mg dose after each dialysis session 7, 8
This regimen maintains mean plasma levels of 6.4 μM, sufficient to inhibit herpes zoster virus (therapeutic range 4–8 μM) while minimizing neurotoxicity risk. 8
Special Considerations for Peritoneal Dialysis
- Patients on continuous ambulatory peritoneal dialysis (CAPD) require the same dose reduction as hemodialysis patients (200 mg twice daily maintenance). 7
- Peritoneal dialysis provides minimal acyclovir clearance compared to hemodialysis; therefore, no supplemental dosing after peritoneal dialysis exchanges is necessary. 2
- Neurotoxicity can occur even at reduced doses in CAPD patients, requiring close monitoring. 9
Common Pitfalls to Avoid
- Never use standard dosing (10 mg/kg every 8 hours IV or 800 mg 5× daily orally) in patients with CrCl < 50 mL/min without adjustment—this leads to rapid drug accumulation and toxicity. 1, 2
- Do not assume oral acyclovir is safer in renal failure—neurotoxicity occurs with both IV and oral formulations when doses are not adjusted. 7, 9
- Avoid concomitant nephrotoxic agents (e.g., ceftriaxone, which increases renal failure risk 19-fold when combined with acyclovir). 6
- Do not delay dose adjustment in patients with fluctuating renal function—recalculate CrCl and adjust dosing if creatinine rises during therapy. 1, 10
Therapeutic Drug Monitoring
- Consider measuring serum acyclovir concentrations in patients with severe renal impairment, critical illness, or suspected toxicity. 10
- Target trough concentrations: 0.8–7.6 mg/L; peak concentrations: 6.3–25.7 mg/L (avoid peaks >25 mg/L to minimize toxicity). 10, 11
- A 10-fold interindividual variability in acyclovir clearance exists even among patients with similar renal function, supporting individualized monitoring in high-risk cases. 10